UNSPSC 51392209: Dexlofexidine or levlofexidine or lofexidine

This classification denotes an alpha-adrenergic agonist with the molecular formula C11H12Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5SPW497X0Z, chemically known as (-)-(r)-2-(1-(2,6-dichlorophenoxy)ethyl)-2-imidazoline. but generally known as levlofexidine, which bears US NIH Compound Identifier 3038503. European Medicines Agency schedules Levlofexidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08461MIG.

The term LEVLOFEXIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). LEVLOFEXIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl.

UNSPSC 51392209 Dexlofexidine or levlofexidine or lofexidine is a Commodity code that appears in state and local procurement activity focused on opioid-response pharmaceuticals and drug management systems, though recent opportunities tagged to this code diverge significantly from its nominal scope. The Seminole County, Florida IFB60459723LAS solicitation, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually—drugs and devices for overdose reversal and controlled substance disposal rather than the alpha-2 agonists named in the code. The Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, solicited vendor capabilities for a direct-to-manufacturer prescription program but did not specify pharmaceutical products by name or UNSPSC alignment. The mismatch between the code's nominal scope and the actual opportunities suggests either tagging inconsistency in the source databases or that dexlofexidine, levlofexidine, and lofexidine occupy a narrow procurement niche within state and local health systems that does not currently register in visible competitive solicitations.

State and local issuing bodies using this code include county health departments (Seminole County) and state health agencies (Texas HHS), but the recent-opportunities block shows limited activity—two records over a recent posting window, neither of which explicitly names the alpha-2 agonists. The Seminole County opportunity required quarterly delivery to a single location with electronic bid submission through the county e-Procurement Portal, a two-year initial term with one-year renewal option, and E-Verify compliance. Geographic concentration appears limited to Florida and Texas based on the current record set, but the sparse activity and scope misalignment suggest this code warrants direct vendor research into state formularies and pharmacy benefit program alignments rather than reliance on posted competitive solicitations to characterize current demand.